Skip to main content
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1992 Jun 1;175(6):1729–1737. doi: 10.1084/jem.175.6.1729

Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients

PMCID: PMC2119233  PMID: 1588290

Abstract

10 patients with borderline and lepromatous leprosy were selected for a prolonged trial with recombinant interferon gamma (rIFN-gamma). Patients received 30 micrograms intradermally for six injections over a 9-d period, and then either 100 micrograms intradermally every 1 mo for 10 mo or every 2 wk for 5 mo (total, 1.2 mg). Erythema nodosum leprosum (ENL) was induced in 60% of the patients within 6-7 mo, as compared with an incidence of 15% per year with multiple drug therapy alone. The mean whole-body reduction in bacterial index over the first 6 mo was 0.9 log units. Cutaneous induration at the intradermal injection sites of greater than or equal to 15 mm predicted the development of a subsequent reactional state. Monocytes obtained from patients receiving the lymphokine demonstrated an increased respiratory burst and a 2.5- 5.1-fold increase in tumor necrosis factor alpha (TNF-alpha) secretion in response to agonists. Patients in ENL had an even higher release of TNF-alpha from monocytes as well as high levels of TNF-alpha in the plasma (mean, 2,000 pg/ml). Thalidomide therapy was required to treat the systemic manifestations of ENL. Control of toxic symptoms with thalidomide was associated with a 50-80% reduction in agonist- stimulated monocyte TNF-alpha secretion. IFN-gamma enhanced the monocyte release of TNF-alpha by 3-7.5-fold (agonist dependent) when added to patient's cells in vitro, and this could be suppressed by the in vitro addition of 10 micrograms/ml of thalidomide.

Full Text

The Full Text of this article is available as a PDF (1.6 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes P. F., Fong S. J., Brennan P. J., Twomey P. E., Mazumder A., Modlin R. L. Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis. J Immunol. 1990 Jul 1;145(1):149–154. [PubMed] [Google Scholar]
  2. Barnhill R. L., McDougall A. C. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J Am Acad Dermatol. 1982 Sep;7(3):317–323. doi: 10.1016/s0190-9622(82)70118-5. [DOI] [PubMed] [Google Scholar]
  3. Cooper C. L., Mueller C., Sinchaisri T. A., Pirmez C., Chan J., Kaplan G., Young S. M., Weissman I. L., Bloom B. R., Rea T. H. Analysis of naturally occurring delayed-type hypersensitivity reactions in leprosy by in situ hybridization. J Exp Med. 1989 May 1;169(5):1565–1581. doi: 10.1084/jem.169.5.1565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Debets J. M., van der Linden C. J., Spronken I. E., Buurman W. A. T cell-mediated production of tumour necrosis factor-alpha by monocytes. Scand J Immunol. 1988 May;27(5):601–608. doi: 10.1111/j.1365-3083.1988.tb02388.x. [DOI] [PubMed] [Google Scholar]
  5. Djeu J. Y., Serbousek D., Blanchard D. K. Release of tumor necrosis factor by human polymorphonuclear leukocytes. Blood. 1990 Oct 1;76(7):1405–1409. [PubMed] [Google Scholar]
  6. Dubravec D. B., Spriggs D. R., Mannick J. A., Rodrick M. L. Circulating human peripheral blood granulocytes synthesize and secrete tumor necrosis factor alpha. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6758–6761. doi: 10.1073/pnas.87.17.6758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gorin I., Vilette B., Gehanno P., Escande J. P. Thalidomide in hyperalgic pharyngeal ulceration of AIDS. Lancet. 1990 Jun 2;335(8701):1343–1343. doi: 10.1016/0140-6736(90)91223-w. [DOI] [PubMed] [Google Scholar]
  8. Hart P. H., Whitty G. A., Piccoli D. S., Hamilton J. A. Control by IFN-gamma and PGE2 of TNF alpha and IL-1 production by human monocytes. Immunology. 1989 Mar;66(3):376–383. [PMC free article] [PubMed] [Google Scholar]
  9. Kaplan G., Britton W. J., Hancock G. E., Theuvenet W. J., Smith K. A., Job C. K., Roche P. W., Molloy A., Burkhardt R., Barker J. The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy. J Exp Med. 1991 Apr 1;173(4):993–1006. doi: 10.1084/jem.173.4.993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kaplan G., Cohn Z. A. The immunobiology of leprosy. Int Rev Exp Pathol. 1986;28:45–78. [PubMed] [Google Scholar]
  11. Kaplan G., Mathur N. K., Job C. K., Nath I., Cohn Z. A. Effect of multiple interferon gamma injections on the disposal of Mycobacterium leprae. Proc Natl Acad Sci U S A. 1989 Oct;86(20):8073–8077. doi: 10.1073/pnas.86.20.8073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kaplan G., Nusrat A., Sarno E. N., Job C. K., McElrath J., Porto J. A., Nathan C. F., Cohn Z. A. Cellular responses to the intradermal injection of recombinant human gamma-interferon in lepromatous leprosy patients. Am J Pathol. 1987 Aug;128(2):345–353. [PMC free article] [PubMed] [Google Scholar]
  13. Kaplan G., Weinstein D. E., Steinman R. M., Levis W. R., Elvers U., Patarroyo M. E., Cohn Z. A. An analysis of in vitro T cell responsiveness in lepromatous leprosy. J Exp Med. 1985 Sep 1;162(3):917–929. doi: 10.1084/jem.162.3.917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Klebanoff S. J., Shepard C. C. Toxic effect of the peroxidase-hydrogen peroxide-halide antimicrobial system on Mycobacterium leprae. Infect Immun. 1984 May;44(2):534–536. doi: 10.1128/iai.44.2.534-536.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Laal S., Bhutani L. K., Nath I. Natural emergence of antigen-reactive T cells in lepromatous leprosy patients during erythema nodosum leprosum. Infect Immun. 1985 Dec;50(3):887–892. doi: 10.1128/iai.50.3.887-892.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lepay D. A., Steinman R. M., Nathan C. F., Murray H. W., Cohn Z. A. Liver macrophages in murine listeriosis. Cell-mediated immunity is correlated with an influx of macrophages capable of generating reactive oxygen intermediates. J Exp Med. 1985 Jun 1;161(6):1503–1512. doi: 10.1084/jem.161.6.1503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Modlin R. L., Gebhard J. F., Taylor C. R., Rea T. H. In situ characterization of T lymphocyte subsets in the reactional states of leprosy. Clin Exp Immunol. 1983 Jul;53(1):17–24. [PMC free article] [PubMed] [Google Scholar]
  18. Molloy A., Gaudernack G., Levis W. R., Cohn Z. A., Kaplan G. Suppression of T-cell proliferation by Mycobacterium leprae and its products: the role of lipopolysaccharide. Proc Natl Acad Sci U S A. 1990 Feb;87(3):973–977. doi: 10.1073/pnas.87.3.973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Moreno C., Taverne J., Mehlert A., Bate C. A., Brealey R. J., Meager A., Rook G. A., Playfair J. H. Lipoarabinomannan from Mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages. Clin Exp Immunol. 1989 May;76(2):240–245. [PMC free article] [PubMed] [Google Scholar]
  20. Nathan C., Squires K., Griffo W., Levis W., Varghese M., Job C. K., Nusrat A. R., Sherwin S., Rappoport S., Sanchez E. Widespread intradermal accumulation of mononuclear leukocytes in lepromatous leprosy patients treated systemically with recombinant interferon gamma. J Exp Med. 1990 Nov 1;172(5):1509–1512. doi: 10.1084/jem.172.5.1509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rao T. D., Rao P. R. Enhanced cell-mediated immune responses in erythema nodosum leprosum reactions of leprosy. Int J Lepr Other Mycobact Dis. 1987 Mar;55(1):36–41. [PubMed] [Google Scholar]
  22. Ridley D. S., Jopling W. H. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966 Jul-Sep;34(3):255–273. [PubMed] [Google Scholar]
  23. Ridley D. S. Reactions in leprosy. Lepr Rev. 1969 Apr;40(2):77–81. doi: 10.5935/0305-7518.19690016. [DOI] [PubMed] [Google Scholar]
  24. Rook G. A., Taverne J., Leveton C., Steele J. The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology. 1987 Oct;62(2):229–234. [PMC free article] [PubMed] [Google Scholar]
  25. Sampaio E. P., Sarno E. N., Galilly R., Cohn Z. A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991 Mar 1;173(3):699–703. doi: 10.1084/jem.173.3.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Sarno E. N., Grau G. E., Vieira L. M., Nery J. A. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. Clin Exp Immunol. 1991 Apr;84(1):103–108. [PMC free article] [PubMed] [Google Scholar]
  27. Sehgal V. N. Reactions in leprosy. Clinical aspects. Int J Dermatol. 1987 Jun;26(5):278–285. doi: 10.1111/j.1365-4362.1987.tb00188.x. [DOI] [PubMed] [Google Scholar]
  28. Valone S. E., Rich E. A., Wallis R. S., Ellner J. J. Expression of tumor necrosis factor in vitro by human mononuclear phagocytes stimulated with whole Mycobacterium bovis BCG and mycobacterial antigens. Infect Immun. 1988 Dec;56(12):3313–3315. doi: 10.1128/iai.56.12.3313-3315.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Van Voorhis W. C., Steinman R. M., Hair L. S., Luban J., Witmer M. D., Koide S., Cohn Z. A. Specific antimononuclear phagocyte monoclonal antibodies. Application to the purification of dendritic cells and the tissue localization of macrophages. J Exp Med. 1983 Jul 1;158(1):126–145. doi: 10.1084/jem.158.1.126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Young J. W., Steinman R. M. Accessory cell requirements for the mixed-leukocyte reaction and polyclonal mitogens, as studied with a new technique for enriching blood dendritic cells. Cell Immunol. 1988 Jan;111(1):167–182. doi: 10.1016/0008-8749(88)90061-5. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES